Malignant melanoma: An emerging and preventable medical catastrophe

被引:6
作者
Creagan, ET
机构
关键词
D O I
10.4065/72.6.570
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The natural history of malignant melanoma, including the diagnosis, prognosis, and treatment options, is reviewed in err attempt to formulate appropriate management strategies. Awareness on the part of clinicians is important, inasmuch as early detection of malignant melanoma offers the best chance for improved survival. Most lesions are excised with a margin of 1 to 3 cm, and follow-up assessment intervals are based on the depth of the primary lesion. Follow-up usually consists of a medical history, physical examination, chest roentgenography, and hematologic and chemistry profiles. Routine use of sophisticated imaging studies is unnecessary because the yield from such san approach has been low. Patients with melanomas thicker than 1.6 mm and those with histologic evidence of involvement of regional lymph nodes are at risk for development of disseminated disease and may be candidates for adjuvant therapy. Hn patients with severe weight loss and poor nutrition because of advanced disease, analgesic agents, stool softeners, and appetite enhancers tare palliative measures that should be considered.
引用
收藏
页码:570 / 574
页数:5
相关论文
共 11 条
[1]   RESULTS OF ADJUVANT INTERFERON STUDY IN WHO MELANOMA PROGRAM [J].
CASCINELLI, N ;
BUFALINO, R ;
MORABITO, A ;
MACKIE, R .
LANCET, 1994, 343 (8902) :913-914
[2]   REGIONAL AND SYSTEMIC STRATEGIES FOR METASTATIC MALIGNANT-MELANOMA [J].
CREAGAN, ET .
MAYO CLINIC PROCEEDINGS, 1989, 64 (07) :852-860
[3]   PSYCHOSOCIAL ISSUES IN ONCOLOGIC PRACTICE [J].
CREAGAN, ET .
MAYO CLINIC PROCEEDINGS, 1993, 68 (02) :161-167
[4]   RANDOMIZED, SURGICAL ADJUVANT CLINICAL-TRIAL OF RECOMBINANT INTERFERON ALFA-2A IN SELECTED PATIENTS WITH MALIGNANT-MELANOMA [J].
CREAGAN, ET ;
DALTON, RJ ;
AHMANN, DL ;
JUNG, SH ;
MORTON, RF ;
LANGDON, RM ;
KUGLER, J ;
RODRIGUE, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2776-2783
[5]  
CREAGAN ET, 1990, J INVEST DERMATOL S, V95
[6]   Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684 [J].
Kirkwood, JM ;
Strawderman, MH ;
Ernstoff, MS ;
Smith, TJ ;
Borden, EC ;
Blum, RH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :7-17
[7]  
Kirkwood John M., 1994, Current Opinion in Oncology, V6, P204, DOI 10.1097/00001622-199403000-00014
[8]   PALLIATIVE CARE AND MELANOMA - THE CARE OF THE PATIENT WITH PROGRESSIVE DISEASE [J].
LICKISS, JN .
WORLD JOURNAL OF SURGERY, 1992, 16 (02) :282-286
[9]  
PRESCOTT LM, 1995, CLIN CANC LETT, V18, P1
[10]  
RUSTHOVEN J, 1995, P AN M AM SOC CLIN, V14, P413